Merck KGaA: targets E25bn in sales by 2025
(CercleFinance.com) - The company's Q1 2023 net sales reached E5.
3bn, up 1.8% y-o-y and up 0.8% in organic terms.
Sales growth was mainly attributable to Healthcare, which recorded significant growth in its business with new medicines, it said. Healthcare sales rose by 6.2% to E1,905m.
EBITDA decreased 2.6% (organically -1.7%) to E1,587m. The main reasons for this were the decline in Display Solutions, as well as significantly lower profit contributions from Covid-19 sales, management said. EPS reached E2.36.
This year Merck KGaA expects net sales of 21.2 to 22.7 billion euros (vs. E22.2bn in 2022), with organic growth of 1% to 4%, EBITDA of E6.7bn (E6.8bn in 2022) and EPS of E8.80 to E9.90.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
3bn, up 1.8% y-o-y and up 0.8% in organic terms.
Sales growth was mainly attributable to Healthcare, which recorded significant growth in its business with new medicines, it said. Healthcare sales rose by 6.2% to E1,905m.
EBITDA decreased 2.6% (organically -1.7%) to E1,587m. The main reasons for this were the decline in Display Solutions, as well as significantly lower profit contributions from Covid-19 sales, management said. EPS reached E2.36.
This year Merck KGaA expects net sales of 21.2 to 22.7 billion euros (vs. E22.2bn in 2022), with organic growth of 1% to 4%, EBITDA of E6.7bn (E6.8bn in 2022) and EPS of E8.80 to E9.90.
Copyright (c) 2023 CercleFinance.com. All rights reserved.